CAR T cells are genetically engineered to produce an artificial receptor on the T-cell surface for use in immunotherapy, which immediately engages its target, results in CAR T-cell proliferation, and effects target cell cytotoxicity. Prior to CAR T-cell therapy, approximately 30% of patients with diffuse large B-cell lymphoma (DLBCL) had an unmet need for a new treatment approach. There are now 3 commercially available CAR T-cell products capable of achieving long-term, disease-free survival in the third line of therapy for patients with relapsed or refractory DLBCL, transformed follicular lymphoma, or primary mediastinal large B-cell lymphoma: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.
Disclosures: Dr. Schuster has disclosed receiving consulting fees from Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, BeiGene, Celgene Corporation, Genentech, Inc., Incyte Corporation, Janssen Pharmaceutica Products, LP, Legend Biotech, Loxo Oncology, Onc., Novartis Pharmaceuticals Corporation, and Regeneron Pharmaceuticals, Inc.; serving as a scientific advisor for Celgene Corporation, Genentech, Inc., Loxo Oncology, Onc., and Novartis Pharmaceuticals Corporation; receiving grant/research support from Genentech, Inc. and Novartis Pharmaceuticals Corporation; and receiving honoraria from Novartis Pharmaceuticals Corporation.